BG107037A - Фармацевтични състави ha инхибитори на гликоген фосфорилаза - Google Patents

Фармацевтични състави ha инхибитори на гликоген фосфорилаза Download PDF

Info

Publication number
BG107037A
BG107037A BG107037A BG10703702A BG107037A BG 107037 A BG107037 A BG 107037A BG 107037 A BG107037 A BG 107037A BG 10703702 A BG10703702 A BG 10703702A BG 107037 A BG107037 A BG 107037A
Authority
BG
Bulgaria
Prior art keywords
alkyl
strands
alkoxy
glycogen phosphorylase
mono
Prior art date
Application number
BG107037A
Other languages
Bulgarian (bg)
English (en)
Inventor
Dennis HOOVER
Ravi Shanker
Dwayne Friesen
Douglas LORENZ
James Alan NIGHTINGALE
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG107037A publication Critical patent/BG107037A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
BG107037A 2000-03-16 2002-08-26 Фармацевтични състави ha инхибитори на гликоген фосфорилаза BG107037A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18994200P 2000-03-16 2000-03-16
PCT/IB2001/000394 WO2001068055A1 (en) 2000-03-16 2001-03-16 Pharmaceutical compositions of glycogen phosphorylase inhibitors

Publications (1)

Publication Number Publication Date
BG107037A true BG107037A (bg) 2003-04-30

Family

ID=22699402

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107037A BG107037A (bg) 2000-03-16 2002-08-26 Фармацевтични състави ha инхибитори на гликоген фосфорилаза

Country Status (32)

Country Link
US (1) US20010053778A1 (is)
EP (1) EP1263414A1 (is)
JP (1) JP2003526654A (is)
KR (1) KR20020081445A (is)
CN (1) CN1418089A (is)
AP (1) AP2002002621A0 (is)
AR (1) AR027656A1 (is)
AU (1) AU2001242669A1 (is)
BG (1) BG107037A (is)
BR (1) BR0109189A (is)
CA (1) CA2403241A1 (is)
CO (1) CO5280087A1 (is)
CZ (1) CZ20022955A3 (is)
EA (1) EA200200858A1 (is)
EE (1) EE200200530A (is)
HU (1) HUP0204583A2 (is)
IL (1) IL151320A0 (is)
IS (1) IS6508A (is)
MA (1) MA26882A1 (is)
MX (1) MXPA02009097A (is)
NO (1) NO20024386L (is)
OA (1) OA12232A (is)
PA (1) PA8513601A1 (is)
PE (1) PE20011184A1 (is)
PL (1) PL360780A1 (is)
SK (1) SK12622002A3 (is)
SV (1) SV2002000343A (is)
TN (1) TNSN01040A1 (is)
TR (1) TR200202184T2 (is)
WO (1) WO2001068055A1 (is)
YU (1) YU67202A (is)
ZA (1) ZA200207290B (is)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006402B1 (ru) * 1999-12-23 2005-12-29 Пфайзер Продактс Инк. Комбинация лекарства и целлюлозного полимера, повышающего концентрацию; способ введения лекарства и водный раствор (варианты)
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
EP1404300B1 (en) 2001-06-22 2009-09-30 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
HUP0400281A3 (en) 2001-06-22 2009-11-30 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug and process for their preparation
EP1469830A2 (en) 2002-02-01 2004-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
RU2278659C9 (ru) 2002-02-01 2007-02-20 Пфайзер Продактс Инк. Способ получения гомогенных, высушенных распылением твердых аморфных дисперсий лекарственного средства с использованием модифицированной установки сушки распылением
JP2005523262A (ja) 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
EP1701704A2 (en) * 2003-12-31 2006-09-20 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
ES2353309T3 (es) 2004-03-08 2011-03-01 Prosidion Ltd. Hidrazidas del ácido pirrolopiridin-2-carboxílico como inhibidores de glucógeno fosforilasa.
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
CN104755504A (zh) * 2012-08-24 2015-07-01 陶氏环球技术有限责任公司 新的具有高分子量和均匀性的酯化纤维素醚
DK3725778T3 (da) 2012-09-11 2021-09-20 Medivation Prostate Therapeutics Llc Formuleringer af enzalutamid
EP3763702B1 (en) * 2013-07-19 2023-12-13 Siga Technologies, Inc. Preparation of amorphous tecovirimat dispersions
CN103709171B (zh) * 2014-01-20 2015-09-16 武汉大学 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
CA2342471C (en) * 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
EP1263414A1 (en) 2002-12-11
IS6508A (is) 2002-08-16
NO20024386D0 (no) 2002-09-13
PL360780A1 (en) 2004-09-20
WO2001068055A1 (en) 2001-09-20
YU67202A (sh) 2006-01-16
HUP0204583A2 (hu) 2003-04-28
MA26882A1 (fr) 2004-12-20
CN1418089A (zh) 2003-05-14
AU2001242669A1 (en) 2001-09-24
IL151320A0 (en) 2003-04-10
CZ20022955A3 (cs) 2003-09-17
CA2403241A1 (en) 2001-09-20
EA200200858A1 (ru) 2003-02-27
EE200200530A (et) 2004-04-15
CO5280087A1 (es) 2003-05-30
ZA200207290B (en) 2003-09-11
BR0109189A (pt) 2003-05-27
SK12622002A3 (sk) 2004-02-03
US20010053778A1 (en) 2001-12-20
JP2003526654A (ja) 2003-09-09
TR200202184T2 (tr) 2003-01-21
OA12232A (en) 2006-05-10
TNSN01040A1 (fr) 2005-11-10
AP2002002621A0 (en) 2002-09-30
KR20020081445A (ko) 2002-10-26
AR027656A1 (es) 2003-04-09
PA8513601A1 (es) 2004-08-31
NO20024386L (no) 2002-11-13
SV2002000343A (es) 2002-07-03
MXPA02009097A (es) 2003-03-12
PE20011184A1 (es) 2001-11-15

Similar Documents

Publication Publication Date Title
BG107037A (bg) Фармацевтични състави ha инхибитори на гликоген фосфорилаза
TWI778268B (zh) 含有葡萄糖激酶啟動劑和sglt-2抑制劑的藥物組合及其製備方法和用途
JP2002504478A (ja) アルドースレダクターゼ阻害剤とグリコーゲンホスホリラーゼ阻害剤との組合せ
WO2006011615A1 (ja) 糖尿病治療剤
AU2006214018A1 (en) Method of treating atherosclerosis, dyslipidemias and related conditions
KR100717570B1 (ko) 치료 효과를 신속하게 개시하는 시클로옥시게나제-2저해제 조성물
JP2011530532A (ja) 固体分子分散物中のｈｃｖプロテアーゼインヒビターの薬学的処方物
KR20210032439A (ko) 염증성 장 질환을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
CN109890379A (zh) 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
AU2010315362A1 (en) Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
WO2002034263A1 (fr) Agents preventifs/remedes destines a l'hypertension portale
US20130302422A1 (en) Pharmaceutical composition for treatment and prevention of kidney diseases
CN110636840A (zh) 预防或治疗眼科疾病的方法
WO2021119033A1 (en) Compositions and methods of treatment
CN101460197A (zh) 有机化合物的组合
WO2009146608A1 (zh) 含有咪唑5-羧酸类衍生物的药用组合物，其制备方法及用途
CN113943284B (zh) 盐酸吡格列酮没食子酸共晶及制备方法和其组合物与用途
WO2014007778A1 (en) COMBINED IMMEDIATE RELEASE FORMULATIONS OF NSAIDs
WO2020246526A1 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤
TW202410894A (zh) Glp1醫藥組合物
EA043018B1 (ru) Твердые дисперсии, содержащие стимулятор sgc, для применения в качестве лекарственного средства
JP2002201128A (ja) 門脈圧亢進症予防・治療剤
WO2022161377A1 (en) A phamaceutical composition comprising a glucopyranosyl derivative
JP2001010975A (ja) 単純網膜症・前増殖網膜症の予防・治療・進展抑制剤
TW201620511A (zh) Ｎｅｐ抑制劑藥物組合及其應用